Breakthrough mRNA vaccine shows potential to fight multiple cancers, raising hope for human cure

Scientists at the University of Florida have developed a new type of mRNA cancer vaccine that triggered strong immune responses in mice, shrinking tumors across various cancer types.

The study, published in Nature Biomedical Engineering, demonstrated that when the vaccine was combined with immune checkpoint inhibitors, it led to significant regression of melanoma, brain, bone, and skin tumors.

The vaccine does not target specific tumor antigens like current personalized mRNA therapies but instead mimics a viral infection, prompting the immune system to launch a broad attack on cancer cells.

Researchers say this approach may work as a "universal" cancer vaccine, suitable for many patients without needing customization.

Lead author Dr Elias Sayour said the treatment “essentially trains the immune system to treat cancer like a virus,” and noted that the mice showed robust anti-tumor activity even when the treatment was applied to multiple tumor models.

Notably, the vaccine increased the presence of PD‑L1 on tumors, making them more susceptible to checkpoint inhibitors already in use.

Following the promising preclinical results, the research team is now preparing for human clinical trials focused on aggressive cancers such as glioblastoma.

While experts are cautiously optimistic, they acknowledge that many preclinical breakthroughs have struggled to translate into human success. Still, the findings mark a major step forward in mRNA cancer research.